Alkermes (STU:8AK) Additional Paid-In Capital : €2,559 Mil(As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Alkermes Additional Paid-In Capital?

Alkermes's quarterly additional paid-in capital declined from Sep. 2023 (€2,814 Mil) to Dec. 2023 (€2,510 Mil) but then increased from Dec. 2023 (€2,510 Mil) to Mar. 2024 (€2,559 Mil).

Alkermes's annual additional paid-in capital increased from Dec. 2021 (€2,477 Mil) to Dec. 2022 (€2,750 Mil) but then declined from Dec. 2022 (€2,750 Mil) to Dec. 2023 (€2,510 Mil).

Alkermes Additional Paid-In Capital Historical Data

The historical data trend for Alkermes's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes Additional Paid-In Capital Chart

Alkermes Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

2,327.43

2,207.60

2,476.52

2,749.97

2,509.77

Alkermes Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															2,744.77	2,747.19	2,813.98	2,509.77	2,558.51

Alkermes Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Alkermes Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Alkermes's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Alkermes (STU:8AK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (STU:8AK) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

ALKS:USA 8AK:Germany

Address

1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6

Website

https://www.alkermes.com

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Alkermes (STU:8AK) Headlines

No Headlines